P5091 (P005091) is a cell permeable, potent and specific inhibitor of deubiquitylating enzyme USP7, which induces elevated p53 and apoptosis in cancer cell lines. P5091-induced cytotoxicity is mediated in part via HDM2-p21 signaling axis and although p53 is upregulated in response to P5091 treatment, the cytotoxic activity of P5091 is not dependent on p53. P5091 induces HDM2 polyubiquitylation and accelerates degradation of HDM2. P5091 displays antiangiogenic activity in vivo. P5091 is well tolerated, inhibits tumor growth and prolongs survival in animal models of cancer.
|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.
|Solubility||DMSO 20 mg/mL|
A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.
Chauhan D, et al. Cancer Cell. 2012 Sep 11;22(3):345-58. PMID: 22975377.
|Related Deubiquitinase Products|
P22077 is a selective inhibitor of ubiquitin-specific protease (USP) 7 with EC50 of 8.6 μM.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2017 AbMole BioScience. All Rights Reserved.